NCT04815356 2026-03-31
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
Newave Pharmaceutical Inc
MacroGenics
Stanford University